

---

# **Gastric Cancer Drug Discoveries**

**what the future holds**

*March 2011*

---



*World Leaders in Health Industry Analysis*



---

**Gastric Cancer Report**

March 2011

ISBN: 978 1 85822 417 6

© Copyright 2011 Espicom Business Intelligence

All rights reserved. No part of this publication may be reproduced or used in any form or by any means graphic, electronic or mechanical, including photocopying, recording, taping or storage in information retrieval systems without the express permission of the publisher.

Every care has been taken to ensure that the information contained in this report is correct. The publisher accepts no liability for decisions made on the basis of information contained herein.

British Library Cataloguing in Publication Data.

A catalogue record for this report is available from the British Library.

# CONTENTS

List of Charts .....	v
<b>EXECUTIVE SUMMARY.....</b>	<b>1</b>
<b>MARKET ANALYSIS.....</b>	<b>2</b>
Current Market .....	2
Next-Generation Chemotherapy.....	2
Targeted Therapy .....	3
Future Market.....	4
<b>SALES FORECASTS .....</b>	<b>7</b>
<b>COMPETITIVE ANALYSIS.....</b>	<b>8</b>
Competitor Ratio Analysis.....	10
<b>RESEARCH AND DEVELOPMENT.....</b>	<b>12</b>
VEGF Pathway Inhibitors .....	13
EGFr Inhibitors .....	13
Other Targeted Therapies of Interest.....	14
Chemotherapy.....	15
<b>BACKGROUND INFORMATION.....</b>	<b>16</b>
What is Gastric Cancer? .....	16
The Stages of Gastric Cancer .....	16
Survival Rates .....	17
Risk Factors for Gastric Cancer.....	17
Preventing Gastric Cancer .....	18
Current Treatments .....	18
Surgery .....	18
Chemotherapy.....	18
Radiation Therapy.....	19
Why are New Treatments Needed? .....	19
Patient Statistics.....	19
<b>GASTRIC CANCER PRODUCTS.....</b>	<b>20</b>
<b>TARGETED THERAPIES.....</b>	<b>22</b>
Approved Products .....	22
Herceptin .....	22
Phase III Products.....	31
Afinitor .....	31
Avastin.....	38
Erbix .....	53
Ramucirumab .....	62
Tykerb/Tyverb.....	66
Phase II Products.....	74
AMG 102.....	74
AMG 386.....	76
ARQ 197.....	79
AUY922 .....	83
GDC-0449.....	86
Nexavar .....	89
Nimotuzumab.....	95
Olaparib .....	102
Telatinib .....	105
Tremelimumab .....	107

TSU-68.....	109
Vectibix.....	111
<b>Phase I Products.....</b>	<b>118</b>
Axitinib.....	118
BMS-833923 .....	118
Brivanib.....	118
CUDC-101 .....	118
Recentin .....	118
Vandetanib.....	118
<b>CHEMOTHERAPY.....</b>	<b>119</b>
<b>Approved Products .....</b>	<b>119</b>
Taxotere .....	119
Teysono .....	132
Xeloda.....	136
<b>Phase II Products.....</b>	<b>145</b>
Alimta .....	145
Ixempra .....	150
Tsetaxel .....	154
<b>APPENDIX .....</b>	<b>157</b>
<b>Phase Transition Probability .....</b>	<b>157</b>
<b>Source Material .....</b>	<b>158</b>

## LIST OF TABLES

<i>The Potential Launch Landscape for Gastric Cancer.....</i>	<i>4</i>
<i>Gastric Cancer Sales Forecasts (2010-2017) .....</i>	<i>7</i>
<i>Competitor Ratio Analysis Scores .....</i>	<i>10</i>
<i>Drugs in Clinical Development for Gastric Cancer .....</i>	<i>12</i>
<i>TNM Stage Grouping.....</i>	<i>16</i>
<i>Five-year Gastric Cancer Survival Rates (US).....</i>	<i>17</i>
<i>Targeted Therapies for Gastric Cancer.....</i>	<i>20</i>
<i>Chemotherapy for Gastric Cancer.....</i>	<i>21</i>
<i>Herceptin Sales by Company (2009-2017).....</i>	<i>30</i>
<i>Herceptin Sales by Indication (2009-2017) .....</i>	<i>30</i>
<i>Afinitor Sales by Indication (2009-2017) .....</i>	<i>37</i>
<i>Avastin Sales by Company (2009-2017) .....</i>	<i>50</i>
<i>Avastin Sales by Indication (2009-2017).....</i>	<i>50</i>
<i>Erbix Sales by Company (2009-2017) .....</i>	<i>60</i>
<i>Erbix Sales by Indication (2009-2017) .....</i>	<i>61</i>
<i>Ramucirumab Sales by Indication (2014-2017) .....</i>	<i>65</i>
<i>Tykerb/Tyverb Sales by Indication (2009-2017).....</i>	<i>72</i>
<i>Studies in Metastatic CRC with EGFR-Targeting Monoclonal Antibodies in Irinotecan-Refractory Patients .....</i>	<i>98</i>
<i>Safety Profiles of Leading Anti-EGFR Products and Nimotuzumab.....</i>	<i>99</i>
<i>Efficacy of Docetaxel in the Treatment of NSCLC Patients Previously Treated with a Platinum-Based CT Regimen (Intent-to-Treat Analysis).....</i>	<i>122</i>
<i>Taxotere Sales by Indication (2009-2017) .....</i>	<i>130</i>
<i>S-1 Sales (2009-2017) .....</i>	<i>135</i>
<i>Xeloda Sales by Company (2009-2017) .....</i>	<i>143</i>
<i>Xeloda Sales by Indication (2009-2017).....</i>	<i>143</i>
<i>Probability of Launch.....</i>	<i>157</i>

## LIST OF CHARTS

<i>Gastric Cancer Sales by Therapy (2010)</i> .....	2
<i>Market Share by Product (2010)</i> .....	4
<i>Market Share of Gastric Cancer Therapies (2010)</i> .....	5
<i>Market Share of Gastric Cancer Therapies (2017)</i> .....	5
<i>Market Share by Product (2017)</i> .....	6
<i>Major Players in Gastric Cancer by Market Share (2010)</i> .....	8
<i>Major Players in Gastric Cancer by Market Share (2017)</i> .....	9
<i>Competitor Ratio Analysis Scores</i> .....	11
<i>HER2 Signalling Pathway</i> .....	22
<i>Herceptin Sales (2009-2017)</i> .....	30
<i>Afinitor Mode of Action</i> .....	31
<i>Afinitor Sales (2009-2017)</i> .....	37
<i>Avastin Mode of Action</i> .....	38
<i>Avastin Sales by Company (2009-2017)</i> .....	49
<i>Avastin Sales by Indication, 2010</i> .....	52
<i>Avastin Sales by Indication, 2017</i> .....	52
<i>Erbix Sales (2009-2017)</i> .....	60
<i>Ramucirumab Sales (2014-2017)</i> .....	65
<i>Tykerb/Tyverb Total Sales (2009-2017)</i> .....	72
<i>Tykerb Sales by Indication, 2017</i> .....	73
<i>AUY922 Mode of Action Within a Cancer Cell</i> .....	83
<i>Nexavar's Dual Mode of Action</i> .....	89
<i>Schematic of EGFr Inhibition in Tumourigenesis</i> .....	111
<i>TAX 317 Survival K_M Curves - Docetaxel 75mg/m2 vs Best Supportive Care</i> .....	123
<i>TAX 320 Survival K_M Curves - Docetaxel 75mg/m2 vs Vinorelbine or Ifosfamide Control</i> .....	124
<i>Taxotere Sales (2009-2017)</i> .....	129
<i>Taxotere Sales by Indication (2010)</i> .....	130
<i>Taxotere Sales by Indication (2017)</i> .....	131
<i>S-1 Sales (2009-2017)</i> .....	134
<i>Xeloda Sales (2009-2017)</i> .....	142
<i>Xeloda Sales by Indication (2010)</i> .....	143
<i>Xeloda Sales by Indication (2017)</i> .....	144